Raymond J. Furey insider trades: Rigel Pharmaceuticals (RIGL) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Raymond reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 5, 2025 | RIGL | ↓ Sell | 2,787 | $21.40 | $60K | Direct | Feb 6, 2025 (1d) |
| Sep 10, 2014 | MNK | ↓ Sell | 5,441 | $85.90 | $467K | Direct | Sep 12, 2014 (2d) |
| Sep 5, 2014 | MNK | ↓ Sell | 15,000 | $85.47 | $1.3M | Direct | Sep 8, 2014 (3d) |
| Sep 2, 2014 | MNK | ↓ Sell | 1,040 | $82.34 | $86K | Direct | Dec 3, 2014 (92d) |
| Sep 2, 2014 | MNK | ↓ Sell | 10,303 | $81.61 | $841K | Direct | Sep 3, 2014 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RIGL insiders
Open-market trades in the last 12 months
About Raymond J. Furey's insider trades
Raymond J. Furey is EVP, GC, CCO & Corp Sec at Rigel Pharmaceuticals (RIGL). Since Sep 2, 2014, Raymond has reported no open-market purchases and 5 sales worth $2.7M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (13 filings), shares withheld for taxes (9 filings), option exercises (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RIGL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.